We chatted to IronRidge Resources' CEO Vincent Mascolo who explains why the company has become a lithium explorer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,202.60
Bid: 1,202.40
Ask: 1,202.80
Change: -13.40 (-1.10%)
Spread: 0.40 (0.03%)
Open: 1,202.20
High: 1,236.80
Low: 1,201.20
Yest. Close: 1,216.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

GSK promises growth this year after 2012 shortfall

LONDON, Feb 6 (Reuters) - GlaxoSmithKline, Britain's biggest drugmaker, renewed its promise to return to growth this year, after failing to deliver a hoped-for sales and margin recovery in 2012. GSK also announced a restructuring of European operations, drug manufacturing and research, desi

6 Feb 13 12:13

London midday: Stocks holding higher for now

By the midday mark the Footsie was continuing to trade slightly higher, tracking overnight gains on Wall Street and in Tokyo. The latter came in response to news that Bank of Japan Governor, Masaaki Shirakawa, will step down on March 19th, almost three weeks ahead of schedule, which some observers

6 Feb 13 12:00

STOCKS NEWS EUROPE-Galapagos tops Brussels risers on GSK tests

Belgian drug development company Galapagos is the top riser in Brussels after it reveals that partner GlaxoSmithKline will start to test one of its molecules to treat two new diseases. GlaxoSmithKline licensed the molecule, known as GSK2586184, in February last year as part of deal to pay f

6 Feb 13 11:07

UPDATE 1-GSK promises to publish detailed drug trial data

* Drugmakers under fire for keeping medicine data secret * New move builds on previous GSK pledge to be more open * GSK will now publish detailed clinical study reports * Industry critic Ben Goldacre says GSK move "excellent" LONDON, Feb 5 (Reuters) - Britain's largest dru

5 Feb 13 18:23

Galapagos says GSK starting trials of its new drug

BRUSSELS, Feb 5 (Reuters) - Belgian biotech company Galapagos said on Tuesday that its partner GlaxoSmithKline (GSK) planned to start Phase II studies into a drug candidate to treat two auto-immune disorders. Galapagos said in a statement that GSK would launch the studies for compound GSK25

5 Feb 13 17:00

GSK promises to publish detailed drug trial data

* UK drugmaker paid $3 bln last year to settle fraud case * Company criticised for keeping medicine data secret * Will publish detailed clinical study reports * Historical data back to 2000 will also be revealed LONDON, Feb 5 (Reuters) - British drugmaker GlaxoSmithKline ,

5 Feb 13 15:34

Wednesday preview: GlaxoSmithKline to report difficult quarter, analysts say

Healthcare giant GlaxoSmithKline is expected to report 'another difficult quarter' when the company unveils its latest results Wednesday, according to analysts. The pharmaceuticals group will post its full-year and fourth quarter financials, a day after announcing it increased its stake in its Indi

5 Feb 13 15:01

UPDATE 1-GSK spends $900 mln to lift stake in India consumer arm

LONDON, Feb 5 (Reuters) - GlaxoSmithKline Plc has lifted its stake in its publicly-listed Indian consumer healthcare subsidiary to 72.5 percent from 43.2 percent, deepening its footprint in emerging markets and non-prescription products. David Redfern, GSK's chief strategy officer, said on

5 Feb 13 09:10

Glaxo invests half a billion pounds in Indian consumer healthcare division

Pharmaceuticals group GlaxoSmithKline (GSK) has upped its stake in its Indian consumer healthcare subsidiary by investing over half a billion pounds in the unit. GSK, which first announced an open offer back in November, has now raised its stake in the Indian publicly-listed division from 43.2% to

5 Feb 13 07:52

GSK lifts stake in Indian consumer unit to 72.5 pct

LONDON, Feb 5 (Reuters) - GlaxoSmithKline has lifted its stake in its publicly-listed Indian consumer healthcare subsidiary to 72.5 percent from 43.2 percent, deepening its footprint in emerging markets and non-prescription products. David Redfern, GSK's chief strategy officer, said on Tues

5 Feb 13 07:45

Key TB vaccine trial fails; more waiting in the wings

* Vaccine failed to offer added protection in babies * Study was first of more than a dozen TB vaccines in human trials By Julie Steenhuysen CHICAGO, Feb 4 (Reuters) - A highly anticipated study of the first new tuberculosis vaccine in 90 years showed it offered no added benefit

4 Feb 13 11:59

Vaccine group funds cervical cancer immunisations for poor

* Eight countries to start pilot projects backed by GAVI * Cervical cancer HPV vaccines are made by Merck and GSK * Over 85 pct of cervical cancer deaths are in poor nations By Kate Kelland LONDON, Feb 4 (Reuters) - The GAVI global vaccines group is to help protect more th

4 Feb 13 00:01

RPT-INSIGHT-Revived search for a TB vaccine may be about to pay off

(Repeats INSIGHT first released earlier on Feb. 1) By Julie Steenhuysen CHICAGO, Feb 1 (Reuters) - After nearly 100 years, researchers could be on the verge of finding a vaccine that would eradicate tuberculosis infections, a scourge that kills 1.4 million people a year. Global

1 Feb 13 12:00

INSIGHT-Revived search for a TB vaccine may be about to pay off

By Julie Steenhuysen CHICAGO, Feb 1 (Reuters) - After nearly 100 years, researchers could be on the verge of finding a vaccine that would eradicate tuberculosis infections, a scourge that kills 1.4 million people a year. Global health experts are eagerly awaiting clinical trial result

1 Feb 13 05:01

UPDATE 3-New AstraZeneca CEO plans to invest through tough year

* Mid-to-high single digit percent fall seen in 2013 sales * EPS to fall significantly more as operating costs rise * Q4 sales $7.28 billion, vs I/B/E/S consensus $7.20 bln * Q4 core EPS $1.56 vs $1.35, helped by tax adjustment * Shares fall 5.4 percent on worse-than-expec

31 Jan 13 12:24

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.